SynthesisBiological trace element research2025
Serum Copper Levels in Chronic Kidney Disease and Hemodialysis Patients: Insights from a Systematic Review and Meta-Analysis.
Synthesis in Biological trace element research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Copper Metabolism-Related Cell Death in Kidney Diseases: Molecular Mechanisms, Disease-Specific Evidence, and Translational Implications.International journal of molecular sciences · 2026Review
- Hyperbaric Oxygen Therapy - a Potential Therapy for Macro- and Trace Elements' Imbalance in Patients with Chronic Kidney Disease?Biological trace element research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCopper is an essential trace element involved in numerous enzymatic functions and physiological processes. Chronic kidney disease (CKD) and hemodialysis (HD) may influence copper homeostasis, yet conflicting findings exist regarding copper levels in these patients and copper levels aren't routinely checked. This systematic review and meta-analysis evaluates serum copper concentrations in CKD and HD patients compared to healthy controls (HC), and assesses changes pre- and post-HD.
methodsA systematic search of PubMed, Scopus, Cochrane Library, EMBASE, and Web of Science was conducted up to February 2025. Observational studies reporting serum copper levels in CKD and HD patients were included. Data analysis were conducted using RevMan software. The data were pooled as standardized mean difference (SMD) and using a random-effects model.
resultsA total of 42 studies with 13,592 participants were included. No significant difference in copper levels was observed between CKD patients and HC (SMD: -0.18, 95% CI: -1.17, 0.80; P = 0.71). However, HD patients had significantly lower copper levels compared to HC (SMD: -0.48, 95% CI: -0.89, -0.07; P = 0.02). Additionally, HD significantly reduced serum copper levels post-treatment compared to pre-HD (SMD: -0.41, 95% CI: -0.62, -0.21; P < 0.0001).
conclusionOur findings suggest that CKD does not significantly impact serum copper levels, whereas HD leads to a significant decrease in copper concentrations. The mechanisms underlying this reduction require further elucidation, and future studies should explore the potential clinical consequences of low copper levels in HD patients.
Indexed as
Identifiers
40304970What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.